ReviewOncoTargets and therapy2022

Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead.

Erica S Tsang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.